The Patent Finder

Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use

Sanofi-Aventis

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 5 of these applications claim priority to application 12/675,799, filed Oct 25, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,980,262Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use
In force
 · High confidence
SanofiIn force
High confidence
US 9,175,087Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use
In force
 · High confidence
SanofiIn force
High confidence
US 9,228,019Humanized ANTI-CXCR5 Antibodies, Derivatives Thereof and Their Use
In force
 · High confidence
SanofiIn force
High confidence
US 9,243,067Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use
In force
 · High confidence
SanofiIn force
High confidence
US 9,815,902Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Uses
In force
 · High confidence
SanofiIn force
High confidence
US 12,655,222Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Uses
In force
 · High confidence
SanofiIn force
High confidence
US 8,647,622Humanized anti-CXCR5 antibodies, derivatives thereof and their use
In force
 · High confidence
SanofiIn force
High confidence
Application 13/794,253Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use
Abandoned
Abandoned Nov 28, 2016
SanofiAbandonedAbandoned Nov 28, 2016
Application 15/725,253Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Use
Abandoned
Abandoned Oct 26, 2021
Sanofi-AventisAbandonedAbandoned Oct 26, 2021
9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Sanofi-Aventis.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited